Should I buy or sell AxoGen stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AxoGen in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AXGN shares. View AXGN analyst ratings or view top-rated stocks .

What is AxoGen's stock price target for 2024?

3 Wall Street analysts have issued 12 month price targets for AxoGen's shares. Their AXGN share price targets range from $9.00 to $12.00. On average, they expect the company's stock price to reach $10.67 in the next twelve months. This suggests a possible upside of 53.7% from the stock's current price. View analysts price targets for AXGN or view top-rated stocks among Wall Street analysts .

How have AXGN shares performed in 2024?

AxoGen's stock was trading at $6.83 on January 1st, 2024. Since then, AXGN stock has increased by 1.6% and is now trading at $6.94. View the best growth stocks for 2024 here .

When is AxoGen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our AXGN earnings forecast .

How can I listen to AxoGen's earnings call?

AxoGen will be holding an earnings conference call on Thursday, May 2nd at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link .

How were AxoGen's earnings last quarter?

AxoGen, Inc. (NASDAQ:AXGN) released its quarterly earnings results on Tuesday, March, 5th. The medical equipment provider reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.20) by $0.11. The medical equipment provider earned $42.92 million during the quarter, compared to analysts' expectations of $42.70 million. AxoGen had a negative net margin of 13.66% and a negative trailing twelve-month return on equity of 22.38%.

What ETF holds AxoGen's stock?

iShares Neuroscience and Healthcare ETF holds 5,003 shares of AXGN stock, representing 0.66% of its portfolio.

What guidance has AxoGen issued on next quarter's earnings?

AxoGen issued an update on its FY 2024 earnings guidance on Wednesday, March, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $177.0 million-$181.0 million, compared to the consensus revenue estimate of $178.9 million.

What is Karen Zaderej's approval rating as AxoGen's CEO?

19 employees have rated AxoGen Chief Executive Officer Karen Zaderej on Glassdoor.com . Karen Zaderej has an approval rating of 100% among the company's employees. This puts Karen Zaderej in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at AxoGen to a friend.

What other stocks do shareholders of AxoGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AxoGen investors own include Advanced Micro Devices (AMD) , Bank of America (BAC) , Intelsat (I) , Intel (INTC) , Micron Technology (MU) , Xilinx (XLNX) , Corbus Pharmaceuticals (CRBP) , Exelixis (EXEL) , NVIDIA (NVDA) and Fossil Group (FOSL) .

How do I buy shares of AxoGen?

Shares of AXGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:AXGN

AxoGen (AXGN) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free AXGN Stock Alerts

$6.94

-0.06 (-0.86%)

(As of 04/17/2024 ET)

Compare

Today's Range: $6.92
▼
$7.15
50-Day Range: $6.94
▼
$10.69
52-Week Range: $3.45
▼
$10.83

Volume: 168,438 shs
Average Volume: 308,285 shs
Market Capitalization: $303.21 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.67

Get AxoGen alerts:

AxoGen MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 53.7% Upside
$10.67 Price Target
Short Interest: Healthy
4.26% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$928,054 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.46) to ($0.22) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.68 out of 5 stars

Medical Sector

633rd out of 913 stocks

Electromedical Equipment Industry

12th out of 20 stocks

3.5

Analyst's Opinion

Consensus Rating
AxoGen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
AxoGen has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
4.26% of the float of AxoGen has been sold short.
Short Interest Ratio / Days to Cover
AxoGen has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in AxoGen has recently increased by 1.76%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
AxoGen does not currently pay a dividend.
Dividend Growth
AxoGen does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AXGN.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for AxoGen this week, compared to 2 articles on an average week.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, AxoGen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $928,054.00 in company stock.
Percentage Held by Insiders
Only 7.21% of the stock of AxoGen is held by insiders.
Percentage Held by Institutions
80.29% of the stock of AxoGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for AxoGen are expected to grow in the coming year, from ($0.46) to ($0.22) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of AxoGen is -13.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of AxoGen is -13.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
AxoGen has a P/B Ratio of 3.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About AxoGen Stock (NASDAQ:AXGN)

AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.

AXGN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AXGN Stock News Headlines

March 26, 2024 | insidertrades.com

AxoGen, Inc. (NASDAQ:AXGN) Insider Sells $35,159.04 in Stock

March 26, 2024 | insidertrades.com

AxoGen, Inc. (NASDAQ:AXGN) CEO Karen L. Zaderej Sells 39,280 Shares

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 16, 2024 | globenewswire.com

Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024

April 9, 2024 | americanbankingnews.com

AxoGen (NASDAQ:AXGN) Shares Pass Above Two Hundred Day Moving Average of $7.18

April 4, 2024 | finance.yahoo.com

Analysts Expect Breakeven For AxoGen, Inc. (NASDAQ:AXGN) Before Long

March 9, 2024 | finance.yahoo.com

Director Gregory Freitag Sells 25,000 Shares of Axogen Inc (AXGN)

March 8, 2024 | finance.yahoo.com

US$13.80 - That's What Analysts Think AxoGen, Inc. (NASDAQ:AXGN) Is Worth After These Results

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 7, 2024 | seekingalpha.com

AxoGen, Inc. (AXGN) Q4 2023 Earnings Call Transcript

March 7, 2024 | markets.businessinsider.com

Axogen’s Strong Growth Prospects and Positive Analyst Outlook Prompt Buy Rating and Increased Price Target

March 6, 2024 | sg.finance.yahoo.com

AxoGen, Inc. (AXGN) stock price, news, quote & history – Yahoo Finance

March 6, 2024 | finanznachrichten.de

Axogen, Inc.: Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results

March 6, 2024 | markets.businessinsider.com

Buy Rating Affirmed: AxoGen’s Robust Growth and Market Potential Drive Positive Outlook

March 6, 2024 | msn.com

AxoGen files $100M mixed securities shelf

March 6, 2024 | finance.yahoo.com

AxoGen Full Year 2023 Earnings: Beats Expectations

March 6, 2024 | finance.yahoo.com

AxoGen, Inc. (NASDAQ:AXGN) Q4 2023 Earnings Call Transcript

March 5, 2024 | investing.com

Axogen Inc (AXGN) Earnings Dates & Reports

March 5, 2024 | msn.com

AxoGen Non-GAAP EPS of -$0.06 beats by $0.02, revenue of $42.9M beats by $1.9M

March 5, 2024 | finance.yahoo.com

Axogen Inc (AXGN) Reports Growth in Revenue and Reduction in Net Loss for Q4 and Full-Year 2023

March 5, 2024 | globenewswire.com

Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results

March 4, 2024 | msn.com

AxoGen Q4 2023 Earnings Preview

February 23, 2024 | ca.finance.yahoo.com

American Well Corporation (AMWL)

February 22, 2024 | benzinga.com

Axogen Stock (NASDAQ:AXGN), Short Interest Report

February 17, 2024 | finance.yahoo.com

AXGN Mar 2024 12.500 call

February 16, 2024 | finance.yahoo.com

3 Best Stocks to Buy for Remarkable Earnings Acceleration

February 13, 2024 | finance.yahoo.com

Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024

See More Headlines

Receive AXGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AxoGen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/05/2024
Today: 4/17/2024
Next Earnings (Confirmed): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Electromedical equipment
Sub-Industry: N/A
Current Symbol: NASDAQ:AXGN
CUSIP: N/A
CIK: 805928
Web: www.axogeninc.com
Phone: (386) 462-6800
Fax: 386-462-6801
Employees: 426
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $10.67
High Stock Price Target: $12.00
Low Stock Price Target: $9.00
Potential Upside/Downside: +53.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.52)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-21,720,000.00
Net Margins: -13.66%
Pretax Margin: -13.66%
Return on Equity: -22.38%
Return on Assets: -11.24%

Debt

Debt-to-Equity Ratio: 0.71
Current Ratio: 2.89
Quick Ratio: 2.14

Sales & Book Value

Annual Sales: $159.01 million
Price / Sales: 1.91
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.22 per share
Price / Book: 3.13

Miscellaneous

Outstanding Shares: 43,690,000
Free Float: 40,538,000
Market Cap: $303.21 million
Optionable: Optionable
Beta: 1.03

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Ms. Karen Zaderej (Age 62)
Chairman, President & CEO
Comp: $852.18k
Mr. Michael Donovan (Age 59)
Vice President of Operations
Comp: $406.02k
Mr. Angelo G. Scopelianos Ph.D. (Age 68)
Chief Research & Development Officer
Comp: $540.91k
Mr. Nir Naor C.F.A. (Age 49)
CPA, L.L.M., M.B.A., Chief Financial Officer
Mr. Harold D. Tamayo
Vice President of Finance & Investor Relations
Mr. Marc A. Began (Age 56)
Executive VP, General Counsel & Chief Compliance Officer
Ms. Doris Quackenbush
Vice President of Sales
Mr. Jens Schroeder Kemp
Chief Marketing Officer
Mr. Erick DeVinney (Age 48)
Chief Innovation Officer
Dr. Ivica Ducic M.D.
Ph.D., Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AXGN Stock Analysis - Frequently Asked Questions

Should I buy or sell AxoGen stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AxoGen in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AXGN shares.
View AXGN analyst ratings or view top-rated stocks.
What is AxoGen's stock price target for 2024?: 3 Wall Street analysts have issued 12 month price targets for AxoGen's shares. Their AXGN share price targets range from $9.00 to $12.00. On average, they expect the company's stock price to reach $10.67 in the next twelve months. This suggests a possible upside of 53.7% from the stock's current price.
View analysts price targets for AXGN or view top-rated stocks among Wall Street analysts.
How have AXGN shares performed in 2024?: AxoGen's stock was trading at $6.83 on January 1st, 2024. Since then, AXGN stock has increased by 1.6% and is now trading at $6.94.
View the best growth stocks for 2024 here.
When is AxoGen's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our AXGN earnings forecast.
How can I listen to AxoGen's earnings call?: AxoGen will be holding an earnings conference call on Thursday, May 2nd at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.
How were AxoGen's earnings last quarter?: AxoGen, Inc. (NASDAQ:AXGN) released its quarterly earnings results on Tuesday, March, 5th. The medical equipment provider reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.20) by $0.11. The medical equipment provider earned $42.92 million during the quarter, compared to analysts' expectations of $42.70 million. AxoGen had a negative net margin of 13.66% and a negative trailing twelve-month return on equity of 22.38%.

What ETF holds AxoGen's stock?: iShares Neuroscience and Healthcare ETF holds 5,003 shares of AXGN stock, representing 0.66% of its portfolio.
What guidance has AxoGen issued on next quarter's earnings?: AxoGen issued an update on its FY 2024 earnings guidance on Wednesday, March, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $177.0 million-$181.0 million, compared to the consensus revenue estimate of $178.9 million.
What is Karen Zaderej's approval rating as AxoGen's CEO?: 19 employees have rated AxoGen Chief Executive Officer Karen Zaderej on Glassdoor.com. Karen Zaderej has an approval rating of 100% among the company's employees. This puts Karen Zaderej in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at AxoGen to a friend.
What other stocks do shareholders of AxoGen own?: Based on aggregate information from My MarketBeat watchlists, some companies that other AxoGen investors own include Advanced Micro Devices (AMD), Bank of America (BAC), Intelsat (I), Intel (INTC), Micron Technology (MU), Xilinx (XLNX), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), NVIDIA (NVDA) and Fossil Group (FOSL).
How do I buy shares of AxoGen?: Shares of AXGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AXGN) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

AxoGen (AXGN) Stock Price, News & Analysis

AxoGen MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Coverage This Week

Company Ownership

Earnings and Valuation

About AxoGen Stock (NASDAQ:AXGN)

AXGN Stock Price History

AXGN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

AXGN Stock Analysis - Frequently Asked Questions

Overall MarketRank^™